Kwality Pharmaceuticals logo

Kwality Pharmaceuticals

KPL NSE

Key Fundamentals

MicrocapPharmaceuticalsHealthcare
Market Cap
₹3,609 Cr
Volatility
Moderate
P/E Ratio
46.64
EBITDA
₹121 Cr
Return on Equity
20.41%
Debt to Equity
0.39
Book Value
₹318.8
52W High
₹3,798.9
52W Low
₹1,561

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Strengths

4
  • Company is expected to give good quarter
  • Company has delivered good profit growth of 34.8% CAGR over last 5 years
  • Company has a good return on equity (ROE) track record: 3 Years ROE 18.1%
  • Company's median sales growth is 27.4% of last 10 years

Weaknesses

3
  • Stock is trading at 11.4 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has high debtors of 203 days.

Growth Rate

Revenue Growth
35.96% higher than 3Y
Net Income Growth
69.1% higher than 3Y
Cash Flow Change
-67.64% lower than 3Y
ROE
34.54% higher than 3Y
ROCE
18.87% lower than 3Y
EBITDA Margin (Avg.)
8.23% lower than 3Y

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 69d ago
AI opinion · based on fundamentals
Risk high

Kwality Pharmaceuticals Ltd is a small-cap healthcare company with a market cap of ₹2,821 Cr, trading at a PE of 41.2x and 8.39x book value. The company has delivered strong profit growth of 35% CAGR over 5 years and ROE of 23% in the last year, but carries high debtor days of 203 and pays no dividend despite consistent profitability.

Bull Case 7
  • Strong profit growth with 35% CAGR over 5 years and TTM profit growth accelerating to 71%
  • Consistent ROE track record averaging 26% over 10 years, with 23% in the last year
  • Robust sales growth of 26% CAGR over 3 years and 36% TTM, indicating sustained demand
  • Median sales growth of 27.4% over last 10 years demonstrates long-term revenue consistency
  • Stock price CAGR of 100% over 3 years and 72% over 5 years reflects strong market re-rating
  • Company is expected to deliver a good upcoming quarter based on operational momentum
  • Long-term compounded profit growth of 44% over 10 years shows durable earnings power
Bear Case 8
  • High debtor days of 203 indicates significant working capital strain and potential collection risk
  • PE ratio of 41.2x is expensive relative to the broader market and leaves little margin of safety
  • Price-to-book of 8.39x is elevated, suggesting the stock prices in substantial future growth
  • Zero dividend yield despite repeated profits suggests poor capital return to shareholders
  • Stock has surged 128% in 1 year, raising the risk of mean reversion or correction
  • Small market cap of ₹2,821 Cr implies lower liquidity and higher volatility risk
  • Debt-to-equity ratio is not disclosed, creating uncertainty around the balance sheet leverage
  • 52-week high and low data unavailable, limiting visibility into recent price range and support levels

This is AI-generated analysis, not financial advice. Do your own due diligence.

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
67
70
78
92
80
90
84
116
111
111
123
157
162
Expenses
54
54
61
71
63
70
67
90
87
86
93
118
121
Operating Profit
14
15
17
21
17
20
18
26
24
25
30
39
41
OPM %
20%
22%
21%
22%
22%
22%
21%
22%
22%
23%
24%
25%
25%
Other Income
0
0
1
-7
0
0
1
1
0
1
0
1
1
Interest
2
2
3
3
2
3
2
2
3
3
2
3
3
Depreciation
5
5
5
5
4
5
5
5
5
5
5
5
5
PBT
7
8
10
6
11
13
11
19
17
18
22
32
34
Tax %
25%
24%
21%
29%
25%
33%
25%
24%
30%
23%
28%
20%
25%
Net Profit
5
6
8
4
8
8
9
14
12
14
16
25
26
EPS in Rs
5.22
6.01
7.41
4.2
8.06
8.16
8.22
13.96
11.5
13.61
15.43
24.38
24.69
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
52
74
98
137
166
139
262
456
251
307
370
503
554
Expenses
49
69
89
126
150
125
233
285
190
241
290
385
419
Operating Profit
3
5
9
12
16
14
29
172
61
66
80
118
135
OPM %
6%
7%
9%
8%
9%
10%
11%
38%
24%
22%
22%
24%
24%
Other Income
0
0
1
1
1
4
2
4
-14
-5
2
2
2
Interest
1
1
2
2
2
3
3
3
7
10
10
11
11
Depreciation
1
2
3
3
3
4
6
11
15
20
18
20
20
PBT
1
2
6
7
11
11
21
162
26
31
54
89
106
Tax %
41%
48%
42%
39%
31%
25%
30%
26%
25%
24%
26%
25%
—
Net Profit
1
1
3
4
8
8
15
120
19
24
40
67
81
EPS in Rs
0.92
1.55
3.23
4.39
7.28
8.02
14.6
116
18.67
22.94
38.41
64.91
78.11
Div. Payout %
0%
0%
9%
0%
0%
0%
0%
0%
0%
0%
0%
0%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
4
5
5
10
10
10
10
10
10
10
10
10
Reserves
15
17
20
19
27
36
51
171
190
214
254
321
Borrowings
8
13
19
26
29
35
41
54
90
98
112
130
Other Liabilities
10
17
26
40
39
52
64
105
70
72
71
130
Total Liabilities
37
51
71
96
105
133
166
341
361
394
447
592
Fixed Assets
13
13
17
20
29
43
57
92
120
139
146
156
CWIP
0
0
0
0
0
0
3
12
14
0
0
17
Investments
1
2
4
5
5
4
5
0
0
0
0
0
Other Assets
24
37
50
70
71
86
102
237
226
255
302
420
Total Assets
37
51
71
96
105
133
166
341
361
394
447
592
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
1
-3
4
-1
14
6
27
61
41
43
53
17
Investing
-1
-2
-7
-6
-12
-18
-23
-63
-48
-26
-29
-35
Financing
1
6
5
5
-2
12
1
6
1
-17
-14
7
Net Cash Flow
1
0
2
-1
0
0
4
3
-6
-1
10
-11
Free Cash Flow
0
-5
-2
-7
2
-12
3
5
-4
17
28
-29
CFO/OP
51
-30
76
21
108
62
115
59
78
67
85
32
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
63
89
84
98
84
79
50
55
104
136
152
203
Inventory Days
61
67
71
54
34
94
38
97
310
187
167
111
Days Payable
40
63
65
80
52
96
58
63
117
106
112
144
Cash Conversion Cycle
85
93
90
73
67
77
30
90
297
217
208
170
Working Capital Days
35
41
20
18
20
43
24
60
118
101
98
128
ROCE %
9%
13%
19%
19%
22%
18%
26%
98%
19%
16%
18%
24%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Kwality Pharmaceuticals insights

57 extracted metrics + investor summaries across FY15–FY26.

Log in — free

Shareholding Pattern

DIIs0.56%Promot.54.86%FIIs3.13%Others10.42%Public31.03%As ofJun 2026

Documents

Frequently Asked Questions about Kwality Pharmaceuticals

What does Kwality Pharmaceuticals Ltd do?
Incorporated in 1983, Kwality Pharma is in the business of manufacturing & trading in Pharmaceuticals & allied products[1]
Where is Kwality Pharmaceuticals Ltd (539997) listed?
Kwality Pharmaceuticals Ltd trades as KPL on the NSE and under code 539997 on the BSE.
Which sector does Kwality Pharmaceuticals Ltd belong to?
Kwality Pharmaceuticals Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Kwality Pharmaceuticals Ltd?
Kwality Pharmaceuticals Ltd has a market capitalisation of ₹3,609 Cr, which places it in the Small Cap band.
What is the PE ratio of Kwality Pharmaceuticals Ltd?
Kwality Pharmaceuticals Ltd trades at a PE ratio of 46.64, against a book value of ₹318.8 per share.
What is the 52-week high and low of Kwality Pharmaceuticals Ltd?
Over the last 52 weeks Kwality Pharmaceuticals Ltd has traded between ₹1,561 and ₹3,798.9.
What is the Return on Equity (ROE) of Kwality Pharmaceuticals Ltd?
Kwality Pharmaceuticals Ltd reported a return on equity of 20.41%. Its debt-to-equity ratio is 0.39.

Company Information

Incorporated in 1983, Kwality Pharma is in the business of manufacturing & trading in Pharmaceuticals & allied products[1]

Website kwalitypharma.com
Listed 2016-07-18
Face Value ₹ 10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/539997.md for Kwality Pharmaceuticals Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List